Pfizer, Protalix Tie Up For Sales Of Gaucher's Drug In Brazil Disappointing
This article was originally published in PharmAsia News
Executive Summary
Not all drug makers in major emerging markets such as Brazil profit heavily by partnering with major global drug makers, and Brazil's Protalix Biotherapeutics's tie up with Pfizer for a Gaucher's disease drug Elelyso (taliglucerase) may be an example.